Nanofármacos

CARRIER MATERIAL FOR LOCALLY RELEASING PARTICULATE SUBSTANCE

Resumen de: US20260263631A1

An object of the present invention is to provide a biocompatible carrier material capable of locally releasing particles.The present inventors have found that by using a non-gelling polymer formed by reversibly bonding a plurality of hydrophilic polymer units as a carrier material, it is possible to locally release particles to an affected part such as an ulcer surface, thereby enhancing gene transduction specificity and reducing off-target effects.

METHODS OF IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTS

Resumen de: US20260263380A1

This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.

MIXED NANO-LIPID DELIVERY SYSTEM FOR mRNA, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: US20260263633A1

Disclosed are a mixed nano-lipid delivery system for mRNA, and a preparation method therefor and a use thereof. The delivery system is composed of an anionic and cationic mixed lipid, PEG2000-DSPE, a buffer system and mRNA; the anionic and cationic mixed lipid is composed of anionic nucleoside phospholipid TPS or CPS and cationic peptide lipid CLD or CLDA; and the buffer system is a PBS or Opti-MEM™ buffer system containing Ca2+ having a concentration 0.1 mM. The delivery system can efficiently deliver mRNA into cells and mice, and can realize long-time stable expression of proteins in vivo. In addition, an HPV E7 mRNA vaccine provided by the present disclosure can successfully activate humoral and cellular immunity in mice, reduce the mortality rate of HPV-related cervical cancer mice, and have good safety.

A LYOPHILIZED RNA COMPOSITION

Resumen de: US20260263371A1

The invention is situated in the field of RNA formulation, in particular to lyophilization of RNA. More specifically, the invention relates to a composition that is lyophilized and a method to obtain a lyophilized composition. Moreover, the present invention provides the use of a reconstituted composition according to the invention in human and/or veterinary medicine.

Targeted Nanomedicine for Treating Arterial Disease

Resumen de: US20260263569A1

This disclosure relates to lipid nanoparticle composition comprising polyamidoamine (PAMAM) dendrimer (G0-C14), cholesterol, polyethylene glycol 2000 (PEG), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol) (DSPE-PEG), dioleoylphospha-tidylethanolamine (DOPE), and PLPP3 mRNA encapsulated by the lipid nanoparticle, and methods for treating arterial disease, including, for example, atherosclerosis, peripheral artery disease, ischemic stroke, and stenosis.

Targeted Nanomedicine for Treating Lung Disorders

Resumen de: US20260263627A1

This disclosure relates to compositions and methods for treating lung disorders, including, for example, Acute Respiratory Distress Syndrome (ARDS), Ventila-tor-Induced Lung Injury (VILI), Acute lung injury (ALI), and other acute and chronic lung disorders. Further, wherein a lipid nanoparticle, comprises: a) a VCAM-1 targeting molecule; and b) an RNA molecule encoding Kriippel-like Factor 2 (KLF2).

NEW METHOD FOR DELIVERING COMPOUNDS OF INTEREST

Resumen de: AU2025231263A1

The present invention provides a delivery system comprising of a first aqueous composition harbouring small particles and a second aqueous composition harbouring larger particles in which the particles of the first and second aqueous compositions may comprise the same or a different compound of interest, wherein said compound of interest preferably is a hydrophobic or amphiphilic compound. In both cases the small particles comprise a partly liquid oil phase at temperatures around about 4°C.

IRON-OXIDE NANOPARTICLE-LOADED MESENCHYMAL STEM CELLS AND USES THEREOF

Resumen de: AU2024432366A1

A composition that includes a stem cell and a coated iron oxide nanoparticle. The coated iron oxide nanoparticle, being present in the cytoplasm of the stem cell, contains a superparamagnetic iron oxide core that is coated with one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker covalently linking the polyethylene glycol group and the silane group. Also provided is a method for treating an inflammatory disorder in which stem cells are cultured in the presence of coated iron oxide nanoparticles and the cultured stem cells are administered to a subject suffering from an inflammatory disorder. Further disclosed is a method for tracking stem cells in vivo by labeling stem cells with coated iron oxide nanoparticles, administering the labeled stem cell to an individual, and obtaining one or more T2 weighted magnetic resonance images of the individual to track the stem cells.

LIPID NANOPARTICLES COMPRISING CODING RNA MOLECULES FOR USE IN GENE EDITING AND AS VACCINES AND THERAPEUTIC AGENTS

Resumen de: AU2025223541A1

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.

DELIVERY COMPOSITIONS

Resumen de: AU2025223640A1

This disclosure provides, for instance, novel lipids suitable for use in lipid nanoparticles, for therapeutic delivery of nucleic acids. Also provided are methods of making and using the lipids.

Novel Anti-HSV Antibody

Resumen de: US20260265348A1

Described is a (first) anti-HSV antibody or an antigen-binding fragment thereof binding to the glycoprotein B (gB) of HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said antibody or antigen-binding fragment has a low dissociation rate kdis of at most 5.0×10−4 s−1, preferably at most 1.0×10−4 s−1, at most 5.0×10−5 s−1, and most preferably at most 2.9×10−5 s−1. Moreover, described is a combination of (A) said (first) anti-HSV antibody or an antigen-binding fragment thereof; and (B) a second anti-HSV antibody or an antigen-binding fragment thereof recognizing/binding to the glycoprotein B (gB) of the HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Further, described is a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or the antigen-binding fragment thereof or the combination of said antibodies and at least one pharmaceutically acceptable excipient. Further, described is an anti-HSV antibody or the antigen-binding fragment t

NUCLEIC ACIDS ENCODING THERAPEUTIC POLYPEPTIDES AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE NUCLEIC ACIDS

Resumen de: US20260263375A1

The disclosure provides lipid nanoparticle compositions comprising nucleic acids encoding RSV antigenic polypeptides. The present disclosure also provides novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

METHODS FOR FUS-BASED DELIVERY OF VIRAL PARTICLES TO THE BRAIN

Resumen de: AU2025212867A1

Provided herein are methods to treat various neurodegenerative disorders comprising delivering a viral particles to the whole brain, including both superficial and deep structures. In some aspects, the viral particles are administered at low dose levels to the CSF, in conjunction with microbubbles followed by application of focused ultrasound (FUS) to a region of interest of the brain, thereby causing entry of the viral particles to the brain.

THERAPEUTIC DELIVERY VECTORS COMPRISING AMPHIPHILIC BLOCK COPOLYMERS

Resumen de: US20260263376A1

A nanoparticle for encapsulation of one or more active pharmaceutical ingredient, said nanoparticle comprising an amphiphilic block copolymer, wherein said amphiphilic block copolymer comprises: i. a hydrophobic polymer block comprising structural units of trimethylene carbonate; and ii. a hydrophilic polymer block comprising structural units of one or more alkylene glycols. A drug delivery vector comprising one or more active pharmaceutical ingredients encapsulated within said nanoparticle. A process for preparing said nanoparticle, the process comprising: i. dissolving said amphiphilic block copolymer in an oligomeric alkylene glycol solution to prepare an alkylene glycol-polymer solution; and ii. hydrating said alkylene glycol-polymer solution by addition of water, an aqueous solution or an aqueous buffer to prepare said nanoparticle. A process for preparing said drug delivery vector by encapsulating one or more active pharmaceutical ingredients within a nanoparticle, wherein said process comprises: i. co-dissolving said amphiphilic block copolymer and said one or more active pharmaceutical ingredients in an oligomeric alkylene glycol solution to prepare an alkylene glycol-polymer solution; and ii. hydrating said alkylene glycol-polymer solution by the addition of water, an aqueous solution or an aqueous buffer to prepare said drug delivery vector. Said drug delivery vector for use as a medicament, preferably for use in the treatment of cancer.

TREG THERAPY

Resumen de: US20260263556A1

The present invention relates to a lipid nanoparticle comprising mRNA encoding FOXP3 and at least a second polypeptide, wherein said lipid nanoparticle comprises a moiety capable of specifically binding to a molecule expressed on a CD4+ T cell and wherein said mRNA is modified to have increased stability as compared to unmodified mRNA.

PROGRAMMABLE DRUG-DEVICE MICRONEEDLE SYSTEM FOR THE DELIVERY AND MONITORING OF DIABETES AND OBESITY MEDICATIONS

Resumen de: US20260263353A1

This invention relates to drug-device core-shell microneedle devices containing anti-diabetes and anti-obesity medications, and transdermal delivery of said medications. The microneedle drug-device system comprises: (a) a two-dimensional array of conical bilayer containing an inner layer with the base diameter ranging from about 100 μm to about 500 μm and the height ranging from about 100 μm about 1200 μm capable of accommodating a known amount of anti-diabetes and/or anti-obesity medications, and a suitable, photostable chromophore or a fluorophore whose absorption and/or emission occurring in the range of 400-900 nm; (b) a larger outer layer that adheres to and encapsulates the inner layer, and protects the inner layer, and (c) a two-dimensional array of cylindrical ‘cap layer’ that aligns with and adheres to the basal surface of core shell bilayer and seals the bilayer to prevent leakage of said medication(s). The apical (i.e., sharp) ends of the conical bilayer array inserts into the skin and are programmed to allow the said medications to effuse out of the bilayer and into the skin in a controlled fashion and to be monitored by photodetection devices.

BIODISSOLVABLE MICRONEEDLE ARRAY-METAL-ORGANIC FRAMEWORK-VACCINE BIOCOMPOSITES FOR EFFECTIVE SKIN IMMUNIZATION AND MANUFACTURING THEREOF

Resumen de: US20260263354A1

Disclosed herein are aspects of a microneedle array comprising a metal-organic framework (MOF)-vaccine biocomposite and methods for using the same. The microneedle array further comprises a dissolvable material that dissolved when inserted into the skin of a subject, thereby releasing the MOF-vaccine biocomposite. The MOF may be selected to dissolve in an acidic environment, thereby targeting the vaccine delivery to specific cellular compartments. Methods for making the MOF-vaccine biocomposite and the microneedle array also are disclosed.

NANOBODY FOR NOROVIRUS

Resumen de: US20260265349A1

The present disclosure relates to the field of nanobodies, therapeutic agents, compositions and methods for the prevention, amelioration and treatment of noroviral infections.

COMPOSITIONS AND METHODS

Resumen de: US20260263372A1

An aqueous dispersion having an aqueous mobile phase and a dispersed phase; wherein the dispersed phase comprises a lipid mixture including a cationically ionisable lipid; and the aqueous mobile phase comprises an anion of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents and RNA, is described. Methods of preparing the aqueous dispersion, nucleic acid-lipid particles and methods of preparing them using the aqueous dispersion, and their use in medicine are disclosed.

ANTI-ALBUMIN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF

Resumen de: AU2025211997A1

Provided are an anti-albumin antibody or an antigen-binding fragment thereof and the use thereof, and an anti-albumin nanobody with improved affinity or an antigen-binding fragment thereof. The anti-albumin antibodies or antigen-binding fragments thereof can bind to albumins from different species with high affinity. In addition, the anti-albumin antibody can be linked to a bioactive effector molecule to form a fusion construct without affecting the activity of the bioactive effector molecule.

Tumor Immunotherapy

Resumen de: US20260263573A1

Disclosed is a composition comprising a closed-loop peptide comprising at least two methionines and at least two sulfonium centers; and a conjugate of a negatively charged immunoadjuvant and a peptide.

UNIVERSAL INFLUENZA MRNA VACCINE AND USE THEREOF

Resumen de: US20260263585A1

A universal influenza mRNA vaccine is used to encode a protein. The resulting protein encoded by the universal influenza mRNA vaccine has a matrix protein 2 extracellular domain (M2e), a hemagglutinin (HA) stem LAH region and a nucleoprotein (NP) of an influenza A virus. The universal influenza mRNA vaccine is used in a mouse animal model. The universal influenza mRNA vaccine can induce strong humoral immune and cellular immune responses, and can protect animal model mice against various influenza A viruses.

MRNA THERAPEUTIC COMPOSITIONS

Resumen de: US20260263575A1

Disclosed herein are mRNA therapeutic compositions including one or more polynucleotides encoding one or more tumor antigenic, immunogenic, or signaling polypeptides, formulated within a lipid reconstructed plant messenger packs (LPMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a mRNA therapeutic composition, comprising reconstituting a film comprising purified PMP lipids in the presence of an ionizable lipid to produce a LPMP comprising the ionizable lipid, and loading into the LPMPs with one or more polynucleotides encoding one or more tumor antigenic or immunogenic polypeptides.

EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES

Resumen de: AU2026220199A1

Abstract Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are exogenously loaded with bioactive cargo or other cargo of interest, such as for therapeutic, industrial, diagnostic, and cosmetic uses. The MEVs have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as diagnostics, and other such uses Abstract

METHODS AND COMPOSITIONS FOR TREATING CANCER USING EXOSOMES-ASSOCIATED GENE EDITING

Nº publicación: US20260263369A1 10/09/2026

Solicitante:

BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Resumen de: US20260263369A1

Provided herein are compositions comprising exosomes comprising CD47 on their surface, and further comprising a CRISPR system. Further provided are methods of using the exosomes for gene editing and the treatment of cancer by gene editing.